IJR News

Pirates seek fifth straight MTN8 title against SundownsSports — 3dMamelodi Sundowns and Orlando Pirates meet in the sold-out MTN8 final at Moses Mabhida Stadium, with Pirates seeking a fifth consecutive title and Sundowns aiming to end a five-year wait for the trophy. Sundowns coach Miguel Cardoso says his side is ready, setting up a clash between two teams that advanced through challenging knockout campaigns.

0

Pirates-Sundowns MTN8 Final Sells OutSports — Oct 2, 2026Orlando Pirates and Mamelodi Sundowns will meet in a sold-out MTN8 final at Durban’s Moses Mabhida Stadium on October 10, with the winner claiming the trophy and a R10 million prize. Pirates are seeking a third straight MTN8 final win over Sundowns, who draw confidence from a recent league victory; Pirates coach Abdeslam Ouaddou says his team is preparing with ambition despite players’ international commitments.

0

Tennessee Rallies Past Auburn 24-14 — Sep 27, 2026Auburn beat Vanderbilt 21-15 for its first home SEC win since 2024, with Omar Mabson’s second-quarter punt block recovered and returned for a touchdown by Cade Carlson proving decisive. The Tigers also stopped a Vanderbilt fake punt, while timely scoring drives and defensive stops helped preserve the win despite a sluggish offensive start.

0

Saudi Arabia, Pakistan and Turkey Activate Defense PactWorld — Oct 3, 2026Saudi Arabia, Turkey and Pakistan have agreed to activate collective-defense measures under the Mecca alliance and swiftly deploy previously agreed forces and military capabilities to Saudi Arabia amid Houthi attacks. The move puts Pakistan’s defense commitments to Riyadh to the test after Islamabad had earlier said a military response was not under discussion.

0

Freed Hostage Has Fiery Message for Former Hamas Captors After Enduring Unfathomable Evil: 'I Won'1 source — 2d

0

Best Colleges Preparing Students for the AI EraRankingAI is reshaping every industry, so students and parents compare universities on dedicated programs, research scale, and real-world tech pipelines.

AstraZeneca Completes $2B Summit Cancer Drug InvestmentBusiness — Oct 2, 2026AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics to accelerate development of ivonescimab, an investigational PD-1/VEGF cancer antibody. The companies are also advancing clinical collaborations that pair ivonescimab with antibody-drug conjugates across several cancers, including lung and breast cancer.

0

Alligator Bioscience names CFO Giléus as CEO from 2027 — 6dAlligator Bioscience named CFO Johan Giléus CEO effective Jan. 1, 2027; he keeps the CFO post after the firm halted mitazalimab and refocused on HLX22.

+1

Rachel Meyers Bregenholt staying until end of 2026 should help steady things before the handoff.

Thousands march toward Islamabad for Khan release — 6dThousands of Imran Khan supporters marched Oct. 4 from Lakki Marwat, 275 km from Islamabad, after PTI-government talks failed; Afridi leads as containers and Section 144 block the capital.

+3

Jared Kim I hope the government reopens talks soon instead of blocking the roads with containers and section 144.

Containers Block Islamabad, Rawalpindi Routes for Khan Rally — Sep 29, 2026Pakistani authorities have blocked major routes in Islamabad and nearby Rawalpindi with shipping containers ahead of an October 4 march by Imran Khan’s PTI party demanding his release, after the protest was postponed from September 27. The barricades have disrupted commutes and businesses; the government says they are for security and crowd control, while PTI leaders condemn them as an attempt to suppress democratic rights.

0

AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial — Sep 30, 2026At EADV 2026, long-term ADlong results showed sustained efficacy and safety with lebrikizumab through week 108, with 92.9% of participants achieving EASI-75. Separately, AbbVie’s Phase 2 trial found all zumilokibart doses beat placebo on the week-16 EASI-75 endpoint, and the mid-dose regimen was selected for Phase 3 development.

0

AstraZeneca invests $2 billion in Summit cancer drug partnership — Sep 28, 2026AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% after-hours ahead of a November 14 FDA decision on ivonescimab.

+1

Marcus Bell This deal could help bring the cancer drug to market faster if the November decision goes well.

Most Influential Women in World HistoryYourlist — RankingFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.

Trontinemab Dementia-Prevention Trial Spans 18 CountriesHealth — Sep 25, 2026Alzheimer’s research is advancing on several fronts, including trials of trontinemab to potentially prevent disease in people without symptoms, experimental tau-targeting therapies, and early research into the naturally occurring peptide catestatin. While approved amyloid-targeting drugs and other candidates offer hope of slowing decline, their effectiveness, safety, and cost remain important concerns.

0

Imfinzi Bladder Combo Wins FDA Priority Review — Sep 25, 2026Up to half of muscle-invasive bladder cancer patients cannot take standard chemo. FDA gave Priority Review to AstraZeneca's IMFINZI-enfortumab combo for them; decision due Q4 2026.

+2

Maya Lindstrom Priority review makes sense here but the 2026 decision date still leaves people waiting too long for access.

Trump Signals Possible End to U.S.-Iran War — Sep 15, 2026Iranian security officials repeated that there will be no negotiations with the United States until Washington complies with Iran’s conditions linked to the Islamabad Memorandum and signals that Tehran’s control of Hormuz and the broader oil situation have changed, criticizing Trump’s mixed messages as irrelevant to the core demands. The officials insist sanctions relief, release of frozen assets, and a regional ceasefire are prerequisites, while the U.S. naval blockade remains a lever in ongoing tensions.

0

Ivonescimab Cuts Death Risk 27% in NSCLC TrialHealth — Sep 13, 2026Ivonescimab significantly extends overall survival versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, with a median OS of 30.8 months versus 22.6 months and a 27% reduction in death risk (HR 0.73). Benefits persisted across key subgroups, including PD-L1 high and squamous disease, and are driving international expansion through the ongoing HARMONi-7 study.

0

Madonna vs Lady GagaYourlist — VS BattleThe Queen of Pop versus the artist who studied at her throne.

GE HealthCare reportedly nears $1B Sofie Biosciences acquisition — Sep 13, 2026GE HealthCare is in advanced talks to acquire Sofie Biosciences for about $1 billion, a move to bolster its Pharmaceutical Diagnostics division by owning the consumable radiopharmaceuticals used with PET scans and to accelerate its radiopharmacy network. The deal would cement recurring revenue from radiotracers and link Sofie’s pipeline to GE HealthCare’s scanner business, potentially expediting access to Sofie’s innovative FAPI programs.

+1

Derek Foss Sofie’s pipeline looks promising but a billion-dollar price tag is steep for what is still early-stage tech.

FDA Extends Exelixis Drug Review to March 2027 — Sep 11, 2026The FDA has extended Exelixis' NDA review for zanzalintinib in combination with atezolizumab/Tecentriq for metastatic colorectal cancer by three months, moving the action date to March 3, 2027 after updated safety and efficacy data were deemed a major amendment. The development of zanzalintinib as a next-generation cancer therapy continues, with the delay potentially impacting timelines for patients, investors, and partners awaiting a decision.

0

Nicole Hardy The FDA's move to examine the new safety data more closely makes sense, though it will likely delay any benefits for those counting on the combination therapy.

Mabrey, Howard Lead 3-Point Contest; Shooting Stars Debuts — Jul 21, 2026Toronto Tempo guard Marina Mabrey headlines the WNBA All-Star 3-point contest in Chicago, leading the league with 82 three-pointers this season after a 53-point game that tied the single-game scoring record. She’ll be joined by Rhyne Howard, Azzi Fudd, Natisha Hiedeman, Bridget Carleton and Janelle Salaun, as the event features new prize money under the league’s latest CBA.

0

Mercury rout Tempo 101-69, ends skid — Aug 30, 2026Phoenix Mercury rolled to a 101-69 win over the Toronto Tempo, with Noemie Brochart and Shay Ciezki each scoring 15 as six Mercury players hit double digits. Alyssa Thomas dished 12 assists as Phoenix snapped a four-game skid, marking the team’s second-largest win margin of the season, while Tempo was without leading scorer Marina Mabrey due to an adductor injury.

0

3-Point Contest Invite Dispute Involving Ionescu, Clark — Jul 21, 2026Caitlin Clark and Sabrina Ionescu will skip the WNBA 3-Point Contest this year, with six participants including Marina Mabrey, Rhyne Howard, Azzi Fudd, Bridget Carleton, Janelle Salaün, and Natisha Hiedeman set to compete. Clark has been stellar for the Fever, highlighted by a 45-point, 10-assist game and multiple Player of the Week honors, as Sophie Cunningham emerges as a potential starter off the bench.

0

Selena Gomez Shines As The Glue Holding ‘Only Murders In The Building’ Together‌ ‌ — Sep 26, 2024(L-R) Steve Martin, Selena Gomez, & Martin Short. DISNEY/ERIC MCCANDLESS. “> At the end of season three of Hulu’s Emmy Award-winning TV megahit Only Murders in the Building, Mabel’s future prospects look…

0

Firefighter and Wife Save Elderly Woman Being Mauled by Dog Pack: 'The Dogs Would've Killed Her'Reporting — Apr 21, 2022On Monday, a 65-year-old woman in Bartlesville, Oklahoma, was going out to get her mail when a pack of three loose dogs spotted her and closed in. Mabel Lackey yelled at them, but in the commotion she fell and the dogs…

0

Former NYPD Chief Calls Big Brian Laundrie Discovery ‘Very Strange,’ Suggests ‘Something Is Amiss’Reporting — Oct 22, 2021A set of very experienced law enforcement eyebrows have been raised over the circumstances in which Brian Laundrie’s remains were found. Laundrie’s remains were found Wednesday in the T. Mabry Carlton, Jr. Memorial…

0

AIM ImmunoTech Secures Europe UK Ampligen PatentBusiness — Aug 31, 2026AIM ImmunoTech won European and UK patent protection for Ampligen’s use in treating Long COVID, with exclusivity through 2041, adding to a growing global IP position around Ampligen. Separately, the U.S. patent office granted Ampligen protection through 2039 for use with pembrolizumab across multiple cancers, reinforcing AIM's oncology strategy and expanding patent coverage in Europe, Japan, and beyond.

0